Erie County Medical Center is recruiting head and neck cancer survivors for the AQUAx2 study. The goal of this study is to determine how effective a new study drug (AAV2-hAQP1) is at helping with dry mouth (xerostomia) caused by radiation therapy. Read More

Adults over the age of 18 years old Have previously completed radiation therapy for head or neck cancer Have not had head or neck cancer for at least 3 years Have not been diagnosed with any other types of cance

The University at Buffalo (UB) Department of Medicine is looking for adults who have prostate cancer that has spread beyond the prostate and continues to grow despite being treated with at least 2 different types of treatment that are approved and known to be effective against prostate cancer. Read More

Adults 18 years or older Have been diagnosed with metastatic castrate resistant prostate cancer (mCRPC) Must have progressed on at least 2 prior approved systemic therapies for mCRPC

The University at Buffalo (UB) Department of Medicine is looking for adults who have chronic lymphocytic leukemia (CLL) for a study to investigate if Panzyga (the study drug) can help with preventing infections. Read More

Adults 18 years or older Have been diagnosed with CLL and Hypogammaglobulinemia

The University at Buffalo (UB) Department of Psychology is looking for adults who have had pain from cancer for a remote study. The goal of the study is to learn more about how cannabis may be used to treat pain from cancer. Read More

Adults 21 years or older Identify as either Black or White Have had cancer in the past 3 years Have had a prescription for opioids and pain for more than 30 days Used/have not used cannabis regularly for the past 3 months

The University at Buffalo (UB) Department of Medicine is recruiting adults diagnosed with prostate cancer for a study. The goal of the study is to see if intermittent fasting (or eating only during certain hours of the day) can help to improve the effectiveness of cancer treatment. Read More

Adults 18 years or older Have been diagnosed with prostate cance

The University at Buffalo is looking for adults needing colorectal surgery for a clinical trial. The goal of this study is to investigate the safety and effectiveness of the COLO-BT (Colorectal Balloon Tube) device for people needing colon resection surgery. Read More

Adults aged 19-80 years old Need colon (rectal) resection surgery

This study enrolls people who have head and neck cancer or tumor. The purpose of this study is to learn about whether levels of HPV (Human Papillomavirus) and a protein (P16) are related to the way people respond to treatment for head and neck cancer. Read More

-Patients at least 18 years of age.
-Patients who have been diagnosed with head and neck squamous cell carcinoma.
-Patients who have a pre-treatment biopsy of a pathologically confirmed p16/HPV positive tumor.

Researchers think the study drug, EPI-7386, may be an effective treatment for metastatic castration-resistant prostate cancer (mCRPC) because the drug works by interfering with the function of the male hormone system that leads to the growth of prostate cancer. Enzalutamide is an androgen receptor inhibitor that works by blocking the action of male hormones (androgens) like testosterone to slow down the growth of prostate cancer. Enzalutamide is approved by the Food & Drug Administration (FDA) and is commonly used as a standard of care option for men with advanced or metastatic castration-resistant prostate cancer. Since EPI-7386 and enzalutamide have not been combined together in humans, we are doing this study to find out whether EPI-7386, in combination with a fixed dose of enzalutamide, compared to standard of care enzalutamide alone, is a safe and effective treatment for men who have mCRPC. Study will be done at Spindrift Clinic location. Read More

1) Males aged 18 years or older
2) Histologically, pathologically, or cytologically confirmed prostate adenocarcinoma
3) Presence of metastatic disease at study entry
4) Naïve to second generation anti-androgens

We are doing this study to learn more about if the combination of medications (durvalumab, tremelimumab and enfortumab vedotin)before and after bladder removal surgery will work and be safe for the treatment of muscle invasive bladder cancer. Also to better understand the disease and associated health problems. Read More

1) Participant must be 18 or older years at the time of screening
2) Histologically or cytologically documented muscle-invasive TCC of the bladder with clinical stage of T2-4aN0-N1M0
3) Medically fit for cystectomy and able to receive neoadjuvant therapy
4) Cisplatin-ineligible

This clinical study investigates a new treatment for prostate cancer. ODM-208 (CYP11A1 inhibitor) is the oral study medication that will be taken together with oral glucocorticoid (dexamethasone) and mineralocorticoid (fludrocortisone) replacement therapy. The purpose of this study is to find a safe and effective dose of ODM-208 for the treatment of prostate cancer. The purpose of this study is also to use the results of this study to support development programs of CYP11A1 inhibitors in prostate cancer and other relevant indications. Read More

1) Males greater than or equal to 18 years. 2) Metastatic disease documented either by a positive bone scan, CT, PET/CT or MRI scan 3) Treatment with at least 1 line of taxane-based chemotherapy in castration-sensitive prostate cancer (CSPC) or in CRPC